AVNS - Avanos Medical, Inc.
NYSE
->
Healthcare
->
Medical Devices
Alpharetta,
United States
Type: Equity
AVNS price evolution
AVNS
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $92.2 | $75.8 | $87.7 | |
| Short term investments | ||||
| Net receivables | $131.9 | $123 | $131.3 | $142.8 |
| Inventory | $161.9 | $163.9 | $165.6 | $163.2 |
| Total current assets | $472.6 | $474.1 | $467.8 | $487 |
| Long term investments | ||||
| Property, plant & equipment | $136 | $140.1 | $140.4 | $144 |
| Goodwill & intangible assets | $1020.6 | $1027.7 | $1035.6 | |
| Total noncurrent assets | $1183.7 | $1193.5 | $1205.4 | |
| Total investments | ||||
| Total assets | $1656.2 | $1657.8 | $1661.3 | $1692.4 |
| Current liabilities | ||||
| Accounts payable | $54.2 | $51.4 | $57 | $56.3 |
| Deferred revenue | ||||
| Short long term debt | $24.6 | $20.9 | $21.4 | |
| Total current liabilities | $212.9 | $208.2 | $205.2 | $234.6 |
| Long term debt | $152.6 | $193.7 | $193.8 | $187.7 |
| Total noncurrent liabilities | $227.6 | $228.2 | $221.5 | |
| Total debt | $218.3 | $214.7 | $209.1 | |
| Total liabilities | $426.5 | $435.8 | $433.4 | $456.1 |
| Shareholders' equity | ||||
| Retained earnings | -$309.7 | -$314 | -$315.8 | -$314.9 |
| Other shareholder equity | -$1.9 | -$37.5 | -$29.5 | -$27 |
| Total shareholder equity | $1222 | $1227.9 | $1236.3 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $87.7 | $127.7 | $118.5 | $111.5 |
| Short term investments | ||||
| Net receivables | $142.8 | $167.9 | $118.2 | $108.6 |
| Inventory | $163.2 | $190.3 | $150.3 | $168.9 |
| Total current assets | $487 | $499.8 | $418.6 | $467.2 |
| Long term investments | ||||
| Property, plant & equipment | $144 | $194.5 | $206.7 | $223.6 |
| Goodwill & intangible assets | $1035.6 | $1070.4 | $942.8 | $960.2 |
| Total noncurrent assets | $1205.4 | $1287.1 | $1176 | $1205.6 |
| Total investments | ||||
| Total assets | $1692.4 | $1786.9 | $1594.6 | $1672.8 |
| Current liabilities | ||||
| Accounts payable | $56.3 | $67.9 | $56.4 | $67.6 |
| Deferred revenue | ||||
| Short long term debt | $21.4 | $19 | $14.7 | $15.5 |
| Total current liabilities | $234.6 | $185.8 | $139.2 | $166.3 |
| Long term debt | $187.7 | $226.3 | $172.8 | $233.3 |
| Total noncurrent liabilities | $221.5 | $309.9 | $191.5 | $250 |
| Total debt | $209.1 | $280 | $187.5 | $248.8 |
| Total liabilities | $456.1 | $495.7 | $330.7 | $416.3 |
| Shareholders' equity | ||||
| Retained earnings | -$314.9 | -$253.1 | -$310.3 | -$315.5 |
| Other shareholder equity | -$27 | $0.3 | -$33.8 | -$28.1 |
| Total shareholder equity | $1236.3 | $1291.2 | $1263.9 | $1256.5 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $170.4 | $171.7 | $166.1 | $173.3 |
| Cost of revenue | $76.1 | $71.3 | $78.3 | |
| Gross Profit | $92.9 | $95.6 | $94.8 | $95 |
| Operating activities | ||||
| Research & development | $6.3 | $7 | $6.8 | |
| Selling, general & administrative | $80.9 | $83.6 | $74.5 | |
| Total operating expenses | $79.3 | $87.2 | $90.6 | $81.3 |
| Operating income | $8.4 | $4.2 | $13.7 | |
| Income from continuing operations | ||||
| EBIT | $6.8 | $3.2 | $11.7 | |
| Income tax expense | $3.6 | $1.9 | $1 | -$2.1 |
| Interest expense | -$2.5 | $3.1 | $3.1 | $3.3 |
| Net income | ||||
| Net income | $4.3 | $1.8 | -$0.9 | $10.5 |
| Income (for common shares) | $1.8 | -$0.9 | $10.5 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $673.3 | $820 | $744.6 | $714.8 |
| Cost of revenue | $293.6 | $370 | $380.3 | $341.5 |
| Gross Profit | $379.7 | $450 | $364.3 | $373.3 |
| Operating activities | ||||
| Research & development | $27.2 | $30.6 | $32.3 | $34.9 |
| Selling, general & administrative | $335 | $341.9 | $300.3 | $332.6 |
| Total operating expenses | $362.2 | $372.5 | $332.6 | $367.5 |
| Operating income | $17.5 | $77.5 | $31.7 | $5.8 |
| Income from continuing operations | ||||
| EBIT | -$44.8 | $75.2 | $9.1 | -$44.9 |
| Income tax expense | $2 | $14.7 | $0.6 | -$33.3 |
| Interest expense | $15 | $10 | $3.3 | $15.6 |
| Net income | ||||
| Net income | -$61.8 | $50.5 | $5.2 | -$27.2 |
| Income (for common shares) | -$61.8 | $50.5 | $5.2 | -$27.2 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | $1.8 | -$0.9 | $10.5 | |
| Operating activities | ||||
| Depreciation | $11.3 | $11.4 | $11.5 | |
| Business acquisitions & disposals | $2.1 | $86.9 | ||
| Stock-based compensation | $3.8 | $3.6 | $4 | |
| Total cash flows from operations | $27.8 | -$8 | $12.7 | |
| Investing activities | ||||
| Capital expenditures | -$5.9 | -$4.1 | -$5.9 | |
| Investments | ||||
| Total cash flows from investing | -$19.9 | -$5.9 | -$2 | $81 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$3.5 | -$8.6 | -$6.4 | |
| Net borrowings | -$1.5 | $8.4 | -$96.6 | |
| Total cash flows from financing | -$21.7 | -$5 | -$0.7 | -$114.7 |
| Effect of exchange rate | $0.1 | -$0.5 | -$1.2 | $1.6 |
| Change in cash and equivalents | $1.3 | $16.4 | -$11.9 | -$19.4 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$61.8 | $50.5 | $5.2 | -$27.2 |
| Operating activities | ||||
| Depreciation | $46.1 | $47.7 | $38.3 | $42.9 |
| Business acquisitions & disposals | $39.4 | -$116.1 | -$4 | |
| Stock-based compensation | $15.8 | $15.9 | $13.2 | $12.1 |
| Total cash flows from operations | $32.4 | $90.9 | $87.3 | -$2.5 |
| Investing activities | ||||
| Capital expenditures | -$17.8 | -$19.3 | -$21 | -$20.2 |
| Investments | ||||
| Total cash flows from investing | $21.6 | -$135.4 | -$21 | -$24.2 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$17.8 | -$43.8 | -$5.3 | $2.5 |
| Net borrowings | -$64.7 | $100.5 | -$50 | -$69.8 |
| Total cash flows from financing | -$94.2 | $56.7 | -$55.3 | -$70 |
| Effect of exchange rate | $0.2 | -$3 | -$4 | $2.9 |
| Change in cash and equivalents | -$40 | $9.2 | $7 | -$93.8 |
News
Fundamentals
| Market cap | $738.96M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 45.95M |
| Revenue | $681.50M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | $15.70M |
| Revenue Q/Q | -0.53% |
| Revenue Y/Y | -9.12% |
| P/E ratio | 47.07 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 1.08 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | $0.34 |
|---|---|
| ROA | 0.94% |
| ROE | N/A |
| Debt/Equity | 0.37 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.22 |
| Quick ratio | 1.46 |